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Abstract 
Purpose: To investigate the effect of capecitabine on apoptosis induction in HCT-15 colon carcinoma 
cells and investigate the underlying mechanism.  
Methods: Phase-contrast microscopy was used for the examination of morphological changes while 
flow cytometry was employed for the analysis of cell cycle distribution, induction of apoptosis, reactive 
oxygen species (ROS) production and expression of caspases. Western blot assay was used for the 
analysis of expression level of apoptosis-related and cell cycle regulatory proteins. 
Results: Capecitabine treatment caused changes in the morphological appearance of HCT-15 cells 
after 48 h. The viability of HCT-15 cells was reduced to 23 % on treatment with capecitabine (5 μM) 
compared to 98 % in the control cultures. Incubation with capecitabine increased the population of HCT-
15 cells in G0/G1 phase to 56.43 % compared to 41.67 % in the control. Capecitabine treatment of 
HCT-15 cells caused condensation of DNA and induced apoptosis in a concentration-dependent 
manner. At 5 μM concentration of capecitabine, apoptosis was induced in 45.74 % of the cells. 
Incubation of HCT-15 cells with capecitabine for 48 h led to a significant increase in the production of 
ROS. Translocation of Endo G and AIF from mitochondria to the nuclei increased significantly (p < 
0.005) on treatment with 5 μM capecitabine. Capecitabine treatment also reduced the expression of 
cyclin E and Cdc25c and promoted the level of caspases, Bax, AIF, Endo G, p21, PARP and p-p53. The 
expression level of Bcl-2 decreased in HCT-15 cells on incubation with 5 μM concentration of 
capecitabine. 
Conclusion: Capecitabine treatment causes inhibition of colon cancer growth via the mitochondrial 
pathway of apoptosis. Thus, capecitabine may have therapeutic application in colon carcinoma 
treatment. 
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Colorectal cancer is globally considered as the 
most common cancer found in people of all age 
groups and alone constitutes 10 % of cancer-
related deaths [1]. It is a malignant neoplasm 
originating from the lining of the colon. Colorectal 
cancer metastasizes to various distant organs 
and its most common target is the liver. One type 
of colon cancer is colitis-associated cancer which 
is characterized by the onset of inflammatory 
bowel disease of ulcerative colitis [2]. It has been 
reported that 15 % of patients with colorectal 
cancer show liver metastases [3]. Among various 
types of solid tumors only in patients with 
colorectal cancer can the survival term be 
increased by surgical extraction of distant 
metastases from various organs such as liver 
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and lungs [4]. The survival of the unresectable 
metastases of colorectal cancer patients can be 
increased by treatment with systemic 
chemotherapy [5].  
 
Cell apoptosis is a programmed mechanism for 
death of unwanted cells which can take place via 
intrinsic or extrinsic pathways [6,7]. Various 
ligands interact with surface receptors (tumor 
necrosis factor) and death receptors leading to 
cell apoptosis through extrinsic pathway [7,8]. 
However, cellular processes like oxidative stress, 
DNA damage and cytotoxic agents lead to 
apoptosis through the intrinsic pathway [7].  
 
In caspase dependent method of apoptosis 
various proteins such as components of Bcl-2 
class are involved in the maintenance of 
activation of caspases [9,10].Treatment of cancer 
by induction of cell apoptosis using 
chemotherapeutic agents is one of the best 
strategies. Therefore, screening of new 
molecules for the development of treatment 
strategy can improve the clinical outcome for 
patients with colorectal cancer. 
 
Capecitabine is a modified derivative of 
fluoropyrimidine aimed to selectively transfer 5-
fluorouracil into tumor cell. The method of 
administration of capecitabine is very simple and 
comfortable. In gastric cancer treatment 
capecitabine is used either singly or in 
combination with other chemotherapeutic agents 
[11]. Administration of higher doses of 
capecitabine to patients of gastric cancer cause 
side effects such as diarrhea, lymphopenia, 
nausea etc. However, lower doses have been 
found to be effective.  
 
In the present study effect of capecitabine on 
viability and apoptosis induction in human colon 
cancer cells was investigated. The study 
demonstrated that capecitabine treatment at 
lower doses causes inhibition of colon cancer 
growth via mitochondrial pathway of apoptosis. 
Thus capecitabine can be a very good candidate 




Chemicals and reagents 
 
Capecitabine was purchased from Roche 
Pharmaceutical Company (Nutley, NJ, USA) and 
its solution was freshly prepared at the time of 
use in dimethylsulfoxide (DMSO). Propidium 
iodide, Triton X-100, Tris-HCl and trypan blue 
were supplied by Sigma Chemical Co (St Louis, 
MO, USA).  
 
Cell culture and cell viability assay 
 
HCT-15 human colon cancer cell line purchased 
from Food Industry Research and Development 
Institute (Hsinchu, Taiwan). The cell cultureswere 
grown in RPMI-1640 (Gibco BRL) containing 10 
% fetal bovine serum (FBS, HyClone). The 
medium was supplemented with 2 mM glutamine 
(Sigma-Aldrich) and antibiotics such as penicillin 
(100 U/mL) and streptomycin (100 µg/mL). The 
cells were cultured in an incubator at 37 oC 
temperature under 5 % CO2 atmosphere.  
 
Determination of cell morphology and 
viability 
 
HCT-15 cells at 4 x 104 cells per well density 
were distributed in 12-well plates and incubated 
for 24 h. The cells were then subjected to 48 h 
incubation with 0, 1, 2, 3, 4 and 5 μM doses of 
capecitabine under an atmosphere of 5 % CO2 at 
37 ˚C. After incubation phase-contrast 
microscope was used to examine the cells for 
changes in morphology. For analysis of viability 
the cells were collected after incubation with 
capecitabine, centrifuged and then subjected to 
PI (5 μg/mL) staining before analysis using flow 
cytometry (Becton-Dickinson, San Jose, CA, 
USA).  
 
Analysis of apoptosis 
 
HCT-15 cells after incubation with or without 
capecitabine for 48 h were collected and 
trypsinized. The cells were then washed twice 
with phosphate-buffered saline and subsequently 
resuspended at a density of 2 x 106 cells per ml 
in binding buffer.  
 
The cells were then treated with 5 µL each of 
annexin-V-fluorescein isothiocyanate and 
propidium iodide (PI) and subjected to incubation 
for 15 min at room temperature. FACScalibur 
Flow Cytometer (BD Biosciences, San Jose, CA, 
USA) was used for the analysis of cell apoptosis. 
 
Analysis of cell cycle 
 
HCT-15 cells after incubation with or without 
capecitabine for 48 h were collected and 
trypsinized. The cells were collected and then 
fixed overnight at 4 oC using 70 % ethyl alcohol. 
The cells were re-suspended in the dark at 37 oC 
for half an hour in PBS supplemented with PI (40 
μg/mL) and RNase (0.1 mg/mL) Triton X-100 
(0.1 %). Flow cytometer connected with an argon 
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ion laser was used for analysis of the cells at a 
wavelength of 490 nm. 
 
Determination of reactive oxygen species 
(ROS) production 
 
HCT-15 cells at density of 2 x 106 cells per mL 
were incubated with indicated doses of 
capecitabine for 48 h. The cells were collected 
and treated with 10 μM solution of 2, 7-
dichlorodihydrofluorescein diacetate (DCFH-DA) 
for half an hour at 37 ˚C. After incubation the 
cells were analyzed using flow cytometry for 
production of reactive oxygen species. 
 
Western blot analysis 
 
HCT-15 cells after incubation with capecitabine 
for 48 h under the appropriate conditions were 
collected and washed two times with ice-cold 
PBS. The cells were then treated with lysis buffer 
[40 mM Tris (pH 8.0), sodium chloride (120 mM), 
NP-40 (0.5 %), sodium or thovanadate (0.1 mM), 
aprotinin (2 µg/mL), leupeptin (2 µg/mL) and 
phenymethylsulfonyl fluoride (100 µg/mL)] to get 
the lysate. From the lysate supernatant was 
collected to determine the concentration of 
proteins (Pierce, Rockford, IL).  
 
Denaturation of extracted proteins was 
performed with sample buffer [Tris-HCl (0.5 M), 
pH 6.8, 4 % SDS, glycerol (20 %), bromophenol 
blue (0.1 %), β-mercaptoethanol (10 %)] for 10 
min at 100 oC. Isolation of the proteins was 
achieved on 6-15 % SDS-PAGE and the proteins 
were subsequently transferred onto PVDF 
membranes.  
 
The non-specific sites in the membranes were 
blocked for 1 h with 5 % non-fat dry milk in Tris-
buffered saline with Tween-20 buffer at room 
temperature. Membrane incubation with primary 
antibodies was performed overnight. Following 
incubation 4 X TBS-T buffer was used for 
washing of the membrane for 15 min followed by 
1 h incubation with horseradish peroxidase-
conjugated anti-rabbit or anti-mouse 
immunoglobin (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA).  
 
Thereafter, 1 X TBS-T buffer was used for 
washing the membrane for 15 min. The complex 
format on interaction of antigen with antibody 
was analyzed using enhanced 
chemiluminescence (ECL) detection system (GE 
Healthcare Biosciences, Pittsburgh, PA). The 
primary antibodies against caspase-9, -3, -8, 
Bax, Bal-2, Endo G, AIF and PARP were 
obtained from R&D Systems (Minneapolis, USA) 
whereas those against Cdc25c, cyclin E, p-
p53and p21were obtained from Santa Cruz 
Biotechnology (CA). 
 
Confocal laser scanning microscopy for 
protein translocation 
 
HCT-15cells were distributed at a density of 2 x 
105 cells per well onto 4-well chamber slides and 
cultured. The cells were incubated without or with 
the indicated concentration of capecitabine for 48 
h. Cells on the slides were fixed for over 20 min 
using 4 % formaldehyde in PBS. The cells were 
permeabilized by treatment with Triton-X 100 
(0.3 %) in PBS for 1 h. The non-specific sites 
blocked with 2 % BSA. Staining of the cells was 
performed overnight by incubation with primary 
antibodies against AIF and Endo G (1 : 100 
dilution). The stained cells were incubated with 
secondary antibody (FITC conjugated goat anti-
mouse IgG at 1 : 100 dilution) and subsequently 
subjected to DNA staining using mitotracker. 
Leica TCS SP2 confocal spectral microscope 




HCT-15cellsat a density of 2 X 105 cells per ml 
were incubated with or without capecitabine for 
48 h. After incubation the cells were subjected to 
DAPI (4, 6-diamidino-2-phenylindole 
dihydrochloride) staining. Then fluorescence 





The data are expressed as mean ± standard 
deviation (SD). Student's t-test was used for the 
analysis of the differences among the groups; p 
< 0.05 was considered statistically significant. 




Capecitabine alters the morphology and 
reduces viability of HCT-15 cells 
 
Phase-contrast microscopy showed changes in 
the morphological appearance of HCT-15 cells 
on incubation with capecitabine. Changes in the 
cell morphology were dependent on the 
concentration of capecitabine. Flow cytometry 
revealed that capecitabine treatment significantly 
(p < 0.005) reduced the viability of HCT-15 cells. 
At 5 μM concentration of capecitabine the 
viability of HCT-15 cells was reduced to 23 % 
compared to 98 % in the control cultures (Figure 
1B). 
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Figure 1: Capecitabine alters the morphology and reduces the viability of HCT-15 cells. Incubation of the cells 
with 1, 2, 3, 4 and 5 μMconcentrations of capecitabine was carried out for 48 h. (A) Changes in cell morphology 
was examined using phase-contrast microscopy after 48 h of treatment. (B) The cell viability was analyzed using 
flow cytometry; p < 0.05 compared to the control cells 
 
Capecitabine increases the population of 
HCT-15 cells in G0/G1 phase 
 
Incubation of HCT-15 cells with capecitabine for 
48 h increased the population of cells in G0/G1 
phase in a concentration dependent manner with 
subsequent reduction in S-phase (Figure 2). 
Capecitabine treatment at 5 μM concentration 
increased the population of HCT-15 cells in 
G0/G1 phase to 56.43 % compared to 41.67 % in 
the control. The population of cells in S-phase 
was decreased to 19.89 % in capecitabine 





Figure 2: Capecitabine arrests cell cycle of HCT-15 cells. Cell incubation for 48 h with 1, 2, 3, 4and 5 μM of 
capecitabine was followed by analysis using flow cytometry; *p < 0.05 in comparison with control 
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Capecitabine treatment of HCT-15 cells 
causes induction of apoptosis 
 
The results from DAPI and Annexin V staining 
revealed that capecitabine treatment of HCT-15 
cells caused condensation of DNA and induced 
apoptosis in concentration dependent manner 
(Figure 3). At 5 μM concentration of capecitabine 
apoptosis was induced in 45.74 % of HCT-15 
cells after 48 h compared to 3.39 % in the 
control. 
 
Capecitabine increases reactive oxygen 
species production (ROS) in HCT-15 cells 
 
Incubation of HCT-15 cells with various 
concentrations of capecitabine for 48 h led to 
increase in the production of ROS in 
concentration dependent manner. The 
production of ROS was significantly higher at 5 
μM concentration of capecitabine after 48 h 
(Figure 4). 
 
Capecitabine increases translocation of Endo 
G and AIF from mitochondria in colon 
carcinoma cells 
 
Incubation of HCT-15 cellsfor 48 h with 
capecitabine increased the translocation of Endo 
G and AIF from mitochondria to the nuclei. The 
expression level of Endo G and AIF proteins was 
significantly (p < 0.005) higher in HCT-15 cells at 




Figure 3: Capecitabine induces apoptosis in HCT-15 cells. The cells after incubation for 1, 2, 3, 4 and 5 μM 
concentration of capecitabine were collected and stained with DAPI and Annexin V for analysis of DNA damage 
and induction of apoptosis; *p < 0.05 compared to control 
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Figure 4: Capecitabine increases reactive oxygen species production (ROS) in HCT-15 cells. The cells were 
incubated with 1, 2, 3, 4 and 5 μM concentration of capecitabine for 48 h and then the production of ROS was 




Figure 5: Capecitabine increases Endo G and AIF 
translocation from mitochondria in colon carcinoma 
cells. The cell incubation with 5 μM concentration of 
capecitabine was performed for 48 h and then the 
expression of Endo G and AIF was analyzed using 
confocal laser microscopy 
 
Capecitabine alters expression of cell cycle 
and apoptosis-related proteins in HCT-15 
cells 
 
Western blot analysis showed that incubation of 
HCT-15 cells with various concentrations of 
capecitabine influenced the expression of p21, p-
p53, cyclin E, Cdc25c, Bax and cleavage-
caspases after 48 h. HCT-15 cells on incubation 
with 5 μM doses of capecitabine reduced the 
expression of cyclin E and Cdc25c and promoted 
the level of caspases-8, -3, Bax, AIF, Endo G, 
PARP, p21 and p-p53. The expression level of 
Bcl-2 was decreased in HCT-15 cells on 





The current study was aimed to investigate the 
effect of various concentrations of capecitabine 
on HCT-15 human colon cancer cells. The 
results showed a decrease in viability and 
increase in apoptosis of HCT-15 cells via 





Figure 6: Capecitabine changes the expression ofproteins involved in regulation of the cell cycle and apoptosis 
in HCT-15 cells. Incubation of the cells with 1, 2, 3, 4 and 5μM capecitabine was performed for 48 h followed by 
analysis using western blot. The expression was compared with β-actin as loading control 
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Incubation of HCT-15 cells with capecitabine led 
to reduction in viability to a marked level based 
on the concentration used. Progression of cell 
cycle through various phases is regulated by 
different kinases which play important role in the 
action of cdc/cdk kinases [12]. Cyclins D/cdk on 
activation regulate progression of G1, E/cdk2 
activation G1/S, A/cdk2 activation S and cyclin A 
and cyclin B/cdk1 regulate progression of G2/M 
phases [13, 14]. Investigation of the underlying 
mechanism of capecitabine induced reduction in 
HCT-15 cell viability revealed arrest of cell cycle 
in G0/G1 phase. TheG0/G1 phase arrest was 
further confirmed by increase in p53 and p21 
expression and decrease in Cdc25c and cyclin E 
level in capecitabine treated cells. Up-regulation 
of Bax expression causes increase in the 
mitochondrial membrane permeability which 
results in activation of caspases and 
subsequently cell apoptosis [15-17]. In HCT-15 
cells incubation with capecitabine induced 
apoptosis significantly and increased the 
activation of caspases.  
 
The mitochondrial translocation of proteins AIF 
and Endo G was increased significantly on 
incubation of HCT-15 cells with capecitabine. 
The level of pro-apoptotic protein (Bax) 
expression was promoted in the cells incubated 
with capecitabine. On the other hand, the anti-
apoptotic protein Bcl-2 expression was 
decreased. It is reported that increase in the 
generation of cellular reactive oxygen species 
induces cell cycle arrest and apoptosis [18, 19]. 
Results from the current study showed that 
incubation of HCT-15 cells with capecitabine led 
to increase in the production of reactive oxygen 
species. There are reports that increase in the 
expression level of p21 in the cells is related with 
the JNK pathway activation [20]. The results from 
the present study showed that capecitabine 
treatment of HCT-15 cells significantly increased 




Capecitabine treatment causes inhibition of colon 
cancer growth via the mitochondrial pathway of 
apotposis. Thus, capecitabine may be useful for 
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